Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Limits Population

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has lifted the clinical hold on development of Dynavax's Hepatitis B vaccine Heplisav, allowing the firm to proceed with Phase III development - but in a smaller market than originally proposed: patients with chronic kidney disease

You may also be interested in...



GSK Cervarix Clears Landmark FDA Vaccine Committee with Okay for Novel Adjuvant

GlaxoSmithKline's two-year delay to do more safety work on the vaccine and specifically on the AS04 adjuvant gets the sponsor past one major milestone with a strong vote on safety for use in girls and young women.

Adjuvanted H1N1 Vaccine Excites FDA Panel, But Jury Is Still Out

Pending further data on adjuvants from firms and NIH, FDA's Vaccines and Related Biological Products Advisory Committee is comfortable with FDA's plans to license unadjuvanted H1N1 flu vaccines under the strain change process.

Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults

Regulators offer option to proceed with the hepatitis B vaccine in kidney disease patients, but can the company bear the risk/cost burden of going it alone until it can repartner?

Related Content

Topics

UsernamePublicRestriction

Register

PS004233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel